Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma multiforme, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low breast cancer, HER2-mutant metastatic NSCLC, and locally advanced or metastatic HER2-positive gastric adenocarcinoma.
KRAS wild-type metastatic colorectal cancer (mCRC) in combination with chemotherapy or as a single agent; locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) in combination with radiation.
Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Ph+ CML, gastrointestinal stromal tumors (GIST), and hypereosinophilic syndrome.
Adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, metastatic HER2-overexpressing breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant.
Adult patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, and chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
First-line and adjuvant treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) solid tumors, triple-negative breast cancer (TNBC), and cervical cancer.
Maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, breast, pancreatic, and prostate cancer.
Advanced melanoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, and MSI-H/dMMR metastatic colorectal cancer.
Multiple myeloma in combination with dexamethasone; maintenance therapy following autologous stem cell transplant; transfusion-dependent anemia due to myelodysplastic syndromes; relapsed mantle cell lymphoma; and follicular lymphoma.
Non-Hodgkin lymphoma (diffuse large B-cell, follicular), chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide, and granulomatosis with polyangiitis.